Skip to main content

Table 5 Budget impact for PAH patients in FC II and FC III receiving beraprost and sildenafila

From: Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia

Year

FC II

FC III

beraprost

sildenafil

beraprost

sildenafil

1

8.6

8.4

6.6

7.5

2

7.0

6.9

5.9

6.5

3

7.1

7.3

6.2

6.8

4

7.4

7.7

6.4

7.1

5

7.7

8.0

6.6

7.4

Total

37.8

38.2

31.8

35.4

  1. aAll costs presented in million USD